世界の希少血友病因子の市場規模は、2022 年に 2 億 9,470 万ドルと推定され、2023 年から 2030 年までに6.9% のCAGRで成長すると予想されます。いくつかの新しい因子が集中して規制機関からの承認を得ています。米国 FDA と、診断率と治療率の向上を目的とした政府の取り組みが、市場の成長を推進する重要な動向の 1 つです。特定の凝固因子が不足しているため、まれなタイプの血友病患者は特有の課題に直面しています。これらの患者の満たされていない医療ニーズに対処する必要があるため、希少な血友病因子の需要が高まっています。COVID-19のパンデミックは進行中および計画中の臨床試験に影響を与えた特定の凝固因子療法に大きく貢献します。直接の面会の制限、新型コロナウイルス感染症関連研究のためのリソースの優先順位、患者の安全への懸念により、多くの治験が保留または延期されなければなりませんでした。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Treatment
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Treatment outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Rare Hemophilia Factors Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Rare Hemophilia Factors Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Rare Hemophilia Factors: Type Estimates & Trend Analysis
4.1. Rare Hemophilia Factors Market: Key Takeaways
4.2. Rare Hemophilia Factors Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Factor I
4.3.1. Factor I market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Factor II
4.4.1. Factor II market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Factor V
4.5.1. Factor V market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Factor VII
4.6.1. Factor VII market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Factor X
4.7.1. Factor X market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Factor XI
4.8.1. Factor XI market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Factor XIII
4.9.1. Factor XIII market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Rare Hemophilia Factors: Treatment Estimates & Trend Analysis
5.1. Rare Hemophilia Factors Market: Key Takeaways
5.2. Rare Hemophilia Factors Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Factor Concentrates
5.3.1. Factor concentrates market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Fresh Frozen Plasma
5.4.1. Fresh frozen plasma market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Cryoprecipitate
5.5.1. Cryoprecipitate market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Rare Hemophilia Factors Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Novo Nordisk
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Biogen
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Bayer Healthcare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Pfizer, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Shire
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Baxalta (Baxter Healthcare)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CSL Behring
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Bio Products Laboratory Ltd.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 3 North America rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 4 North America rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 7 Canada rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 8 Canada rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 9 Europe rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 10 Europe rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 11 Europe rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 12 Germany rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 13 Germany rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 14 UK rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 15 UK rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 16 France rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 17 France rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 18 Italy rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 19 Italy rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 20 Spain rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 21 Spain rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 22 Sweden rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 23 Sweden rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 24 Norway rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 25 Norway rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 26 Denmark rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 27 Denmark rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 28 Asia Pacific rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 30 Asia Pacific rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 31 China rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 32 China rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 33 Japan rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 34 Japan rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 35 India rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 36 India rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 37 Australia rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 38 Australia rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 39 Thailand rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 40 Thailand rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 41 South Korea rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 42 South Korea rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 43 Latin America rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 44 Latin America rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 45 Latin America rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 47 Brazil rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 48 Mexico rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 49 Mexico rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 50 Argentina rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 51 Argentina rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 56 South Africa rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 59 UAE rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 60 UAE rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 61 Kuwait rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 62 Kuwait rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
List of Figure
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Rare hemophilia factors: Market outlook
Fig. 9 Rare hemophilia factors: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Rare hemophilia factors market driver impact
Fig. 15 Rare hemophilia factors market restraint impact
Fig. 16 Rare hemophilia factors market strategic initiatives analysis
Fig. 17 Rare hemophilia factors market: Type movement analysis
Fig. 18 Rare hemophilia factors market: Type outlook and key takeaways
Fig. 19 Factor I market estimates and forecasts, 2018 - 2030
Fig. 20 Factor II market estimates and forecasts, 2018 - 2030
Fig. 21 Factor V market estimates and forecasts, 2018 - 2030
Fig. 22 Factor VII market estimates and forecasts, 2018 - 2030
Fig. 23 Factor X market estimates and forecasts, 2018 - 2030
Fig. 24 Factor XI market estimates and forecasts, 2018 - 2030
Fig. 25 Factor XIII market estimates and forecasts, 2018 - 2030
Fig. 26 Rare hemophilia factors market: Treatment movement analysis
Fig. 27 Rare hemophilia factors market: Treatment outlook and key takeaways
Fig. 28 Factor concentrates market estimates and forecasts, 2018 - 2030
Fig. 29 Fresh frozen plasma market estimates and forecasts, 2018 - 2030
Fig. 30 Cryoprecipitate market estimates and forecasts, 2018 - 2030
Fig. 31 Others market estimates and forecasts, 2018 - 2030
Fig. 32 Global rare hemophilia factors market: Regional movement analysis
Fig. 33 Global rare hemophilia factors market: Regional outlook and key takeaways
Fig. 34 North America market estimates and forecasts, 2018 - 2030
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030
Fig. 36 Canada market estimates and forecasts, 2018 - 2030
Fig. 37 Europe. market estimates and forecasts, 2018 - 2030
Fig. 38 UK market estimates and forecasts, 2018 - 2030
Fig. 39 Germany market estimates and forecasts, 2018 - 2030
Fig. 40 France market estimates and forecasts, 2018 - 2030
Fig. 41 Italy market estimates and forecasts, 2018 - 2030
Fig. 42 Spain market estimates and forecasts, 2018 - 2030
Fig. 43 Sweden market estimates and forecasts, 2018 - 2030
Fig. 44 Norway market estimates and forecasts, 2018 - 2030
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 47 Japan market estimates and forecasts, 2018 - 2030
Fig. 48 China market estimates and forecasts, 2018 - 2030
Fig. 49 India market estimates and forecasts, 2018 - 2030
Fig. 50 Australia market estimates and forecasts, 2018 - 2030
Fig. 51 Thailand market estimates and forecasts, 2018 - 2030
Fig. 52 South Korea market estimates and forecasts, 2018 - 2030
Fig. 53 Latin America market estimates and forecasts, 2018 - 2030
Fig. 54 Brazil market estimates and forecasts, 2018 - 2030
Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
Fig. 56 Argentina market estimates and forecasts, 2018 - 2030
Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
Fig. 60 UAE market estimates and forecasts, 2018 - 2030
Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030
